Can donor immune cells help fight pancreatic cancer after surgery?

NCT ID NCT06730009

Recruiting now Disease control Sponsor: Medigen Biotechnology Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding donor natural killer (NK) cells to standard chemotherapy can help prevent cancer from coming back after surgery for pancreatic or bile duct cancer. About 42 adults who had their tumor removed will receive either chemotherapy alone or chemotherapy plus NK cell infusions. The trial first finds the safest dose of NK cells, then compares how long people stay cancer-free in each group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: donor natural killer (NK) cells combined with chemotherapy (S-1, leucovorin, oxaliplatin, gemcitabine)
What this could lead to: If it works, this could point toward a way to delay or prevent cancer recurrence after surgery for pancreatic or bile duct cancer.
What could go wrong: This is an early, small trial (42 people) testing a new cell therapy for the first time in humans. The added benefit over chemotherapy alone is unproven, and there may be unknown side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA RESECTABLE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cholangiocarcinoma malignant pancreatic neoplasm pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHOLANGIOCARCINOMA RESECTABLE PANCREATIC CARCINOMA STAGE II

Contacts and locations

Locations

National Cheng Kung University Hospital
RECRUITING

Tainan, 138, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.